New DEA Cannabis Guidelines: Can Small Farms Survive?
How do we keep a living legacy from becoming legend?
I’ve been traveling through Northern California, walking farms, sitting at people’s tables and listening to what it takes to keep going.
These are family businesses. Sometimes one person, sometimes a couple, sometimes a few people doing nearly everything themselves: growing, maintaining the property, managing compliance, finding buyers and trying to have a life together.
We’ve seen sungrown flower going for around $200 a pound in Southern California. Meanwhile, farmers I’ve spoken with tell me they can barely afford to make $300 a pound work.
But they have families to feed. They need money now. So they’re accepting what they can, even when they tell me those prices cannot sustain their farms. These are observations and accounts from this trip, not a statewide price benchmark.
Selling the crop is not the same as making a living. Sometimes it means accepting a loss because your family needs groceries today.
That is the reality against which we need to examine the new DEA cannabis guidelines—and what they could mean for the people already struggling to remain in the legal market.
Follow our U.S. Cannabis Policy & News Tracker for ongoing developments. This standalone analysis reflects information reviewed November 1, 2026.
What the new DEA cannabis guidelines actually change
On October 30, the Department of Justice announced initial federal registrations for more than 900 medical cannabis dispensaries across seven states:
Alabama
Florida
Mississippi
South Dakota
Texas
Virginia
West Virginia
All seven states already authorized medical cannabis in some form, including Texas’s restricted low-THC medical program. Six had medical-only legalization. Virginia had already legalized adult possession and home cultivation, but its licensed recreational retail market is not scheduled to open until July 2027.
These are federal registrations for qualifying state-licensed dispensaries, not the creation of medical programs in seven previously prohibition-only states.
That distinction does not diminish the significance. Patients and advocates fought to establish these programs. Federal recognition of qualifying medical activity is meaningful progress.
But the announcement does not establish that more dispensaries have opened, prices have fallen or additional patients can obtain products. Those are outcomes we should track.
We can acknowledge the progress while asking who gets access to its benefits—and who remains outside.
Sources: DOJ’s October 30 registration announcement, Texas’s medical program and Virginia’s Cannabis Control Authority.
Federal recognition comes with boundaries
The federal framework covers qualifying Schedule III medical marijuana activities. It does not authorize recreational sales. Marijuana outside the order remains subject to Schedule I controls while a separate process considers broader rescheduling.
State licensure alone does not automatically secure federal registration.
Applicants need qualifying state medical authorization and the appropriate federal registration for their activities. DEA evaluates applications, and manufacturers face additional review involving inspections, production controls and quotas. Registered operations must meet applicable security, inventory and recordkeeping requirements.
Cultivation falls within the federal manufacturer category. A family farm therefore needs to understand how its activities fit this framework—not assume the dispensary registration process answers its questions.
There are published requirements. The question is whether those requirements, and their application to existing state systems, are sufficiently clear and workable for the people being asked to navigate them.
What happens to farms whose buyers enter the federal system?
DEA’s October 30 guidance explains which businesses can participate in the Schedule III medical supply chain: DEA registrants and qualifying “timely applicants.”
Timely applicants must have submitted complete applications and fees between April 28 and June 26, maintain the required state medical license and still have applications pending.
Simply applying now does not provide the same interim authority.
Qualifying timely applicants are expected to verify their trading partners and establish compliant supply chains by November 29, 2026. Transactions with ineligible partners could become grounds for denying an application or revoking a registration.
There is an inventory exception: qualifying timely dispensary and distributor applicants may continue otherwise authorized activities with existing stock acquired before the guidance, including inventory from suppliers outside the qualifying group. The guidance also provides a limited accommodation for testing laboratories under specified conditions.
The practical concern is that a farm outside the federal pathway could lose medical-market buyers.
That does not establish that every California farm will be excluded. It does mean a registration decision can affect businesses beyond the dispensary receiving approval.
A farm cannot survive without buyers. A potential federal pathway means little if the farmer cannot afford the transition into it.
Why California’s mixed market faces difficult questions
DEA has challenged a Minnesota dispensary’s registration because its state license permits both medical and recreational sales, among other objections involving the state’s framework.
The business can contest that action. It is not a final court ruling excluding every mixed-market operator nationwide.
Nevertheless, it raises an immediate concern for states where medical patients and adult-use customers rely on overlapping businesses and supply chains.
California allows qualifying retailers to separate combined medical and adult-use licenses into distinct licenses. That offers flexibility, but it does not guarantee DEA approval.
California recreational dispensaries can continue under applicable state and local law. This announcement does not cancel their state licenses. Their adult-use activities, however, remain outside the federal medical authorization.
For an independent operator, these distinctions create consequential decisions about business structure, suppliers, records and professional advice.
Every hour spent resolving those questions comes from somewhere: finding shelf space, maintaining the farm, collecting payments or being with family.
Sources: Marijuana Moment’s reporting on dual-purpose licenses and California DCC’s federal rescheduling resources.
Spend first. Find out whether you qualify later.
Pursuing registration can require spending money before approval is certain.
Legal advice. Accounting. Applications. Changes to procedures or business structure. Time spent documenting trading partners and understanding which activities are authorized.
If approval is denied, the business may already have paid for work it cannot recover or use as intended.
The money has left the bank account whether the application succeeds or not.
Potential tax relief does not eliminate that risk.
Section 280E restricts deductions for businesses trafficking in Schedule I or II controlled substances. Qualifying Schedule III medical activities have a path out of that restriction, while recreational activities remain subject to it.
But 280E does not simply turn on whether someone labels a business “compliant.” A registration denial alone does not determine the tax treatment of every expense. Treasury has identified transition treatment and allocation of expenses across mixed activities as issues for guidance.
Operators cannot assume that every transition expense will be immediately deductible.
And even an allowable deduction is not reimbursement. It reduces taxable income; it does not return every dollar spent.
A possible future deduction cannot pay today’s attorney invoice or replace a buyer who stops ordering.
The legal risk deserves plain language
Federal medical registration is not blanket protection for everything a company does.
Unauthorized manufacture and distribution of controlled substances remain subject to federal law. Depending on the conduct and applicable legal requirements, operating outside federal authorization can carry criminal consequences. Adult-use activity is not protected by this medical framework.
That does not mean every paperwork error results in an arrest. Registration sanctions, civil penalties and criminal prosecution are different outcomes with different requirements.
But those distinctions must be understandable before operators commit their harvest, inventory or savings.
One concern I hear is that learning to comply has too often involved discovering a problem only after it becomes expensive.
A business might survive a correction. It might not survive interrupted sales, a lost license or the cost of defending itself.
The danger is a transition in which people trying to operate legally cannot afford to get the answers wrong.
The hemp restrictions add another threat to access
Separate federal hemp-definition changes are approaching.
Most are scheduled for December 11, 2026, unless further federal action changes the deadline. Certain exclusions for cannabinoids not capable of being naturally produced by the plant begin November 12.
The revised definition includes a 0.4 mg per-container ceiling for finished cannabinoid products covering total THC and specified similar-effect cannabinoids. It also changes other thresholds and excludes certain manufactured cannabinoids.
This is not a ban on every hemp or CBD product. But many existing full-spectrum CBD products could lose the federal hemp exemption because of their THC content.
Businesses may face reformulation, inventory decisions and lost revenue. People relying on affected products may face disrupted access.
Medical registration and hemp restrictions are separate developments. Their consequences can still arrive in the same household, business or community.
Sources: Minnesota’s Office of Cannabis Management on the federal changes and the statutory hemp definition.
When access disappears, the need does not
Research supports taking that disruption seriously.
A study of 93 veterans participating in a free-access cannabis program found that, among respondents answering the substitution questions, 30% reported substituting cannabis for alcohol and 46.7% for prescription medications.
A separate COVID-era survey of 353 medical cannabis users found that approximately 40% of those who started or increased other medications or substances attributed that change to altered medical cannabis access. That percentage applies to the subgroup—not everyone surveyed.
These self-reported findings do not establish what every patient will do or prove that these new policies will cause overdose deaths.
They do show why continuity matters.
Taking away a product does not take away someone’s pain, sleeplessness or need for support.
Studies: Loflin and colleagues: veterans with access to free medicinal cannabis and Boehnke and colleagues: medication and substance-use increases during COVID-19.
When the farms struggle, the whole town feels it
Being up here, you see that this reaches beyond cannabis businesses.
You see empty storefronts and quiet shops. In places like Garberville and Redway, people describe communities they remember as bustling—and the weariness of working harder for less.
A farmer’s income does not stay on the farm. It helps pay for groceries, restaurant meals, repairs, supplies, housing and wages.
When that spending disappears, the loss travels.
Cannabis policy is not the only force shaping these towns. The new DEA guidance did not cause the empty storefronts already here.
The question is what another barrier could add to communities already worn down—and how much more they can absorb.
The economic consequences belong in this discussion before another closure becomes a statistic.
How do we keep a living legacy from becoming legend?
We can preserve photographs. Record interviews. Tell stories about what these communities built.
But documenting their disappearance is not the same as helping them survive.
These families cannot manufacture another margin. They cannot pay for a transition with a harvest they have not sold. Restructuring does not guarantee a purchase order.
Federal recognition should come with clear explanations, realistic implementation support and a pathway small operators can afford to navigate.
Ask your U.S. representative and senators to protect patient access, address the approaching hemp restrictions and press for workable federal participation for independent businesses. Ask regulators how operators can resolve eligibility questions and correct problems before consequences escalate.
We should also demand transparency about who receives approval, who is denied and why.
A living legacy remains living while the people carrying it can keep doing the work.
If those families cannot afford to stay, we risk celebrating their history while watching their future disappear.
Is this what legalization was supposed to look like?
Keep following the reporting
Thank you to Beard Bros Pharms for consistently sharing the latest developments and helping keep our community informed. Their posts helped bring these stories to my attention.
Credit to Marijuana Moment and Tom Angell for the reporting linked throughout this article. Please read and support their work, including their coverage of the 900-plus registrations, dual medical/adult-use licensing and DEA’s supplier guidance.
For continuing coverage, visit our Cannabis Policy & News Tracker.
This article is for educational and advocacy purposes and is not legal or tax advice. Requirements and deadlines can change; verify current information before making business decisions.
Comments